Cargando…

CD4+ but not CD8+ cells are essential for allorejection

The generation of knockout mice with targeted gene disruption has provided a valuable tool for studying the immune response. Here we describe the use of CD4 and CD8 knockout mice to examine the role of CD4+ and CD8+ cells in initiating allotransplantation rejection. Pretreatment with a brief course...

Descripción completa

Detalles Bibliográficos
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1996
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192869/
https://www.ncbi.nlm.nih.gov/pubmed/8920888
_version_ 1782147337045409792
collection PubMed
description The generation of knockout mice with targeted gene disruption has provided a valuable tool for studying the immune response. Here we describe the use of CD4 and CD8 knockout mice to examine the role of CD4+ and CD8+ cells in initiating allotransplantation rejection. Pretreatment with a brief course of depletive anti-CD4 monoclonal antibody therapy allowed permanent survival of heart, but not skin, allografts transplanted across a major histocompatibility barrier. However, skin as well as heart grafts were permanently accepted in the CD4 knockout mice. Transfer of CD4+ cells into CD4 knockout recipient mice 1 d before skin engraftment reconstituted rejection, demonstrating that CD4+ cells are necessary for initiating rejection of allogeneic transplants. Major histocompatibility complex disparate heart and skin allografts transplanted into CD8 knockout recipients were rejected within 10 d. This study demonstrates that CD4+ but not CD8+ T cells are absolutely required to initiate allograft rejection.
format Text
id pubmed-2192869
institution National Center for Biotechnology Information
language English
publishDate 1996
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21928692008-04-16 CD4+ but not CD8+ cells are essential for allorejection J Exp Med Articles The generation of knockout mice with targeted gene disruption has provided a valuable tool for studying the immune response. Here we describe the use of CD4 and CD8 knockout mice to examine the role of CD4+ and CD8+ cells in initiating allotransplantation rejection. Pretreatment with a brief course of depletive anti-CD4 monoclonal antibody therapy allowed permanent survival of heart, but not skin, allografts transplanted across a major histocompatibility barrier. However, skin as well as heart grafts were permanently accepted in the CD4 knockout mice. Transfer of CD4+ cells into CD4 knockout recipient mice 1 d before skin engraftment reconstituted rejection, demonstrating that CD4+ cells are necessary for initiating rejection of allogeneic transplants. Major histocompatibility complex disparate heart and skin allografts transplanted into CD8 knockout recipients were rejected within 10 d. This study demonstrates that CD4+ but not CD8+ T cells are absolutely required to initiate allograft rejection. The Rockefeller University Press 1996-11-01 /pmc/articles/PMC2192869/ /pubmed/8920888 Text en This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Articles
CD4+ but not CD8+ cells are essential for allorejection
title CD4+ but not CD8+ cells are essential for allorejection
title_full CD4+ but not CD8+ cells are essential for allorejection
title_fullStr CD4+ but not CD8+ cells are essential for allorejection
title_full_unstemmed CD4+ but not CD8+ cells are essential for allorejection
title_short CD4+ but not CD8+ cells are essential for allorejection
title_sort cd4+ but not cd8+ cells are essential for allorejection
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2192869/
https://www.ncbi.nlm.nih.gov/pubmed/8920888